Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377522 | 0.90 | TSHR (0.48) | BCHEL3MBTL1PPARGPPARAMAOB | |
| SCHEMBL6660289 | 0.84 | TDP1 (0.50) | BCHEL3MBTL1TDP1LTA4HEPHX2 | |
| SCHEMBL4768663 | 0.84 | TDP1 (0.50) | BCHEL3MBTL1TDP1LTA4HEPHX2 | |
| SCHEMBL14503417 | 0.83 | ORAI1 (0.54) | BCHEL3MBTL1TDP1CHRM3MEN1 | |
| SCHEMBL5387254 | 0.81 | MRGPRX4 (0.44) | L3MBTL1PPARGPPARAMAOBMEN1 | |
| SCHEMBL5368731 | 0.80 | KCNH2 (0.41) | L3MBTL1TDP1PPARAMAOBMEN1 | |
| SCHEMBL5373718 | 0.80 | TSHR (0.44) | BCHEL3MBTL1TDP1MAOBLTA4H | |
| SCHEMBL5377051 | 0.77 | CNR2 (0.46) | MAOBMEN1KMT2A | |
| SCHEMBL5377020 | 0.77 | ORAI1 (0.48) | TDP1PPARGPPARA | |
| SCHEMBL5373560 | 0.76 | TSHR (0.50) | PPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | claimed |
| US-7217701-B2 | Intracellular calcium concentration increase inhibitors | KATSUHIKO MIKOSHIBA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | CAB39, BPGM, ORAI1 | BCHE 82/4885L3MBTL1 1889/4885TDP1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.